4 Healthcare Stock Stories Ready For a Midweek Investment Checkup
Eli Lilly and Co. (NYSE:LLY): Closing price $54.16
On Wednesday, Eli Lilly announced that 31 abstracts in all will be presented at the 49th European Association for the Study of Diabetes Annual Meeting in Barcelona, September 23 through 27. Through seven presentations, Lilly will share Phase III data for dulaglutide, which is its investigational GLP-1 receptor agonist, and Phase II data for LY2605541, its investigational novel basal insulin analog. Besides that, 17 abstracts will be presented by Boehringer Ingelheim on behalf of the Alliance with Lilly. Additionally, Lilly will present seven more abstracts, including research from its early-stage pipeline.